Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ilginatinib |
Synonyms | |
Therapy Description |
Ilginatinib (NS-018) inhibits JAK2, including JAK2 V617F, as well as SRC family members, including SRC, FYN, and YES, potentially leading to decreased cell proliferation (PMID: 24413068, PMID: 22829185, PMID: 29941953). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ilginatinib | NS-018 | JAK2 Inhibitor - ATP competitive 15 SRC Inhibitor 31 YES Inhibitor 3 | Ilginatinib (NS-018) inhibits JAK2, including JAK2 V617F, as well as SRC family members, including SRC, FYN, and YES, potentially leading to decreased cell proliferation (PMID: 24413068, PMID: 22829185, PMID: 29941953). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F | hematologic cancer | sensitive | Ilginatinib | Preclinical | Actionable | In a preclinical study, cells expressing JAK2 V617F were sensitive to treatment with Ilginatinib (NS-018), demonstrating cell growth inhibition and increased apoptotic activity in culture and improved survival in transgenic mouse models (PMID: 22829185). | 22829185 |
JAK3 A572V | acute myeloid leukemia | predicted - resistant | Ilginatinib | Preclinical - Cell culture | Actionable | In a preclinical study, an acute myeloid leukemia cell line harboring JAK3 A572V was insensitive to treatment with Ilginatinib (NS-018) in culture (PMID: 22829185). | 22829185 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04854096 | Phase II | Ilginatinib | Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis | Terminated | USA | TUR | POL | ITA | GBR | DEU | 3 |